
Discovery of Modulators of Protein-Protein Interactions: Current Approaches and Limitations
Keywords: ABT-737; Alpha-helices; BH3-helix; Bcl-2; Bcl-2 family; Bcl-XL; DNA replication; HCS assays; HDM2; HematideTM; IC50 9 nM; Janus kinases 2; Ligand-based drug discovery; Multiple Protein Structure; Myc-Max dimer; Normal Mode Analyses; Nuclear magnetic resonance (NMR)spectroscopy; PDZ; PTB; Protein-protein interactions; SH2; SH3; SMAC; Thr803; Trp800; Val807; WW; X-ray crystallography (XRC); allosteric binding sites; anti-apoptotic members; biochemical assay; c-Myc-Max heterodimer; cIAP-1; cIAP-2; calmodulin; cancer; computer-aided drug discovery; drug discovery; erythropoietin; fragment-based drug discovery; hematopoietic growth hormone; high-throughput screening; hotspots; human serum albumin; isothermal titration calorimetry; ligandbased pharmacophore; ligands; low-affinity binders; lung cancer; lymphomas; mass spectrometry; p53; p53-MDM2/HDM2; peptide based drug discovery; protein secondary structure mimetics; receptor-based pharmacophore; sheets; signal transduction; smMLCK; small molecules; small-molecule modulators; surface plasmon resonance (SPR); terephthalamide scaffold; tethering; tri-substituted imidazole backbone; tumor suppressor protein; tumorigenesis; turn mimetic scaffolds; turns; undruggable
Document Type: Research Article
Publication date: February 1, 2011
- Editorial Board
- Information for Authors
- Subscribe to this Title
- Ingenta Connect is not responsible for the content or availability of external websites
- Access Key
- Free content
- Partial Free content
- New content
- Open access content
- Partial Open access content
- Subscribed content
- Partial Subscribed content
- Free trial content